About us ?

History, Value & DNA

Divider text here

It is currently estimated that 60% of all known human infectious diseases are of animal origin. The same is true for 75% of emerging human infections and 80% of pathogens that can be used as vectors of bioterrorist attacks. Rapid changes in lifestyles and in breeding and production methods favour interspecies exchanges as well as the transmission to humans of animal pathologies (referred to as zoonoses).

Full 1

VitamFero's teams are well aware of the strong links that exist between animal health and human health as well as their associated economic, social and environmental challenges. As such, the teams are very much in tune with the "one-health" concept, which was best illustrated by Charles Mérieux when he claimed that there are "no borders that separate animal health and human health"..

Since its inception, VitamFero has been investing consistently in its R&D operations while developing its technology, which is based on the creation of next generation attenuated apicomplexan parasite strains. This enables us to provide concrete solutions to global health problems caused by infections that originate primarily in production animals.

Using this integrated approach, VitamFero and its teams are committed daily to prevent and treat these infections and contribute to greater overall sanitary safety through the improvement of animal health.

Our ambition: to ensure that effective vaccines that are easy to use and easily accessible are widely available in order to combat the various agents that are responsible for infectious diseases that affect livestock.

Notre stratégie de développement 

Divider text here
Actuellement, aucun vaccin antiparasitaire n’est disponible en médecine humaine. Ceux qui existent en santé animale sont, pour l’essentiel, très imparfaits et sont loin de satisfaire au cahier des charges optimal.
Apportant une réelle rupture technologique, VitamFero se propose de développer au cours des 4 à 5 prochaines années :
  • un vaccin anti-toxoplasmose ovin,
  • un vaccin anti-toxoplasmose félin,
  • un vaccin anti-néosporose bovin.
  • un vaccin anti-cryptosporidiose bovin.
qui, pour leur enregistrement et leur distribution, feront l’objet d’accords de partenariat et de licence avec une ou des entreprises multinationales du vaccin. Dans cette perspective, VitamFero est d’ores et déjà à la recherche de partenaires industriels avec lesquels elle envisage des co-développements.